UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023802
Receipt number R000027425
Scientific Title A Phase II Study of biweekly Carboplatin, nab-paclitaxel, and concurrent Thoracic radiation therapy for Patients with local advanced Non-small cell Lung Cancer
Date of disclosure of the study information 2016/08/28
Last modified on 2019/02/16 00:31:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Phase II Study of biweekly Carboplatin, nab-paclitaxel, and concurrent Thoracic radiation therapy for Patients with local advanced Non-small cell Lung Cancer

Acronym

A Phase II Study of biweekly Carboplatin, nab-paclitaxel, and concurrent Thoracic radiation therapy for Patients with local advanced Non-small cell Lung Cancer

Scientific Title

A Phase II Study of biweekly Carboplatin, nab-paclitaxel, and concurrent Thoracic radiation therapy for Patients with local advanced Non-small cell Lung Cancer

Scientific Title:Acronym

A Phase II Study of biweekly Carboplatin, nab-paclitaxel, and concurrent Thoracic radiation therapy for Patients with local advanced Non-small cell Lung Cancer

Region

Japan


Condition

Condition

locally advanced Non-small cell Lung Cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to assess the effectiveness and safety of biweekly carboplatin, nab-paclitaxel, and concurrent thoracic radiation therapy for patients with local advanced non-small cell lung cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

2-year survival rate

Key secondary outcomes

Response rate, Progression free survival, Over all survival, Adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Combination of biweekly calboplatin:AUC=4 plus nab-paclitaxel(100mg/m)with concurrent thoracic radiotherapy 2Gy/day for 30 times

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1) Patient with pathologically or cytologically proven non-small cell lung cancer
2) Patient with stage IIIA or IIIB desease
3) Patient who has not been previously treated for lung cancer, including chemotherapy, radiotherapy, and operation
4) V20 < 35%
5) Patient who has at least one or more measurable lesion
6) ECOG performance status (PS): 0-1
7) Patient aged 20-74 years old
8) Adequate organ function.

9) Patient who are considered to survive for more than 3 months.
10) Written informed consent.

Key exclusion criteria

1) T3N1
2) Superior vena cava syndrome.
3) Lymph node metastases of opposite side hilum, malignant pleuritis, malignant pericarditis, lymphangitis.
4) With active double cancer.
5) Active infection.
6) Other serious disease condition (idiopathic pulmonary fibrosis, interstitial lung disease, renal failure, liver failure, Cerebral Vascular Disorder, unstable angina, cardiac infarction, Myocardial Infarction, poorly controlled diabetes mellitus,etc).
7) Grade2< peripheral neuropathy.
8) Severe drug allergy.
9) Pregnancy or lactation.
10) Patient whose participation in the trial is judged to be inappropriate by the attending doctor.

Target sample size

28


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Sadatomo Tasaka

Organization

Hirosaki University Graduate School of Medicine

Division name

Department of Respiratory Medicine

Zip code


Address

Zaifu-cho 5, Hirosaki, 036-8562, Japan.

TEL

0172-33-5111

Email

tasaka@hirosaki-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hisashi Tanaka

Organization

Hirosaki University Graduate School of Medicine

Division name

Department of Respiratory Medicine

Zip code


Address

Zaifu-cho 5, Hirosaki, 036-8562, Japan.

TEL

0172-33-5111

Homepage URL


Email

xyghx335@gmail.com


Sponsor or person

Institute

Hirosaki University

Institute

Department

Personal name



Funding Source

Organization

Hirosaki University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

弘前大学病院(青森県),靑森県立中央病院(青森県)弘前中央病院(青森県),国立病院機構弘前病院(青森県)
八戸市立市民病院(青森県)


Other administrative information

Date of disclosure of the study information

2016 Year 08 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 07 Month 01 Day

Date of IRB


Anticipated trial start date

2016 Year 08 Month 01 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2019 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2016 Year 08 Month 28 Day

Last modified on

2019 Year 02 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027425


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name